Inpharma 1601 - 18 Aug 2007 ■ Measles, mumps and rubella (MMR) revaccination induces a protective antibody response in most children with HIV and immune recovery after HAART, according to researchers from Thailand. Data were evaluated from 51 such children (mean age 10.2 years) who received a single dose of MMR vaccine. At 4 weeks after revaccination, the proportions of patients who achieved protective antibody levels for measles, mumps and rubella were 90%, 78% and 100%, respectively; proportions at 24 weeks were 80%, 61% and 94%, respectively (n = 49). There was no significant difference in the prevalence of protective antibodies in children with or without confirmed prior vaccination. Aurpibul L, et al. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clinical Infectious Diseases 45: 637-642, No. 5, 1 Sep 2007 801058551 1 Inpharma 18 Aug 2007 No. 1601 1173-8324/10/1601-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

MMR revaccination after HAART in kids with HIV

Download PDF Report

View
213
Download
0

Embed Size (px)

Citation preview

Page 1: MMR revaccination after HAART in kids with HIV

Inpharma 1601 - 18 Aug 2007

■ Measles, mumps and rubella (MMR) revaccinationinduces a protective antibody response in mostchildren with HIV and immune recovery after HAART,according to researchers from Thailand. Data wereevaluated from 51 such children (mean age10.2 years) who received a single dose of MMRvaccine. At 4 weeks after revaccination, theproportions of patients who achieved protectiveantibody levels for measles, mumps and rubella were90%, 78% and 100%, respectively; proportions at24 weeks were 80%, 61% and 94%, respectively(n = 49). There was no significant difference in theprevalence of protective antibodies in children with orwithout confirmed prior vaccination.Aurpibul L, et al. Response to measles, mumps, and rubella revaccination inHIV-infected children with immune recovery after highly active antiretroviraltherapy. Clinical Infectious Diseases 45: 637-642, No. 5, 1 Sep2007 801058551